Get Social With Us

Turn-Key, High Yield Biomanufacturing Facility For Sale – Act Fast!

It is common knowledge that monoclonal antibodies are frequently used at much higher doses than other recombinant products, leading to potential demands of tens to hundreds of kilograms or more. With MAbs representing the majority of the top ten selling biopharmaceuticals and a record number of antibody products in development, demand for mammalian capacity has been on the increase. If you’re looking to stay ahead of the curve and meet the anticipated demand for your products, now is your chance to acquire a fully functional, FDA-approved commercial-scale mammalian cell culture manufacturing facility with a proven track record of high-yield monoclonal antibody production!

I recently had an opportunity to tour the original ImClone Erbitux bulk biologics manufacturing facility located just 30 miles from Newark Liberty International Airport and 35 miles from New York City in the bustling biotech hub of Branchburg, NJ. The manufacturing facility at 36 ImClone Drive, Branchburg, is centrally located with excellent access to a highly experienced biotech labor force as well as an extensive transportation, distribution and logistics network. During my visit, I was extremely impressed with the condition of the facility and its potential. While GMP manufacturing operations at the facility have been stopped, all equipment and support systems are well maintained and appear to be in great working order. Specifically designed to manufacture monoclonal antibodies and MAb fusion proteins, this facility represents a unique opportunity to obtain a high-yielding, turn-key facility faster and more economically than building a new manufacturing plant. Companies in the market for primary or additional capacity would be remiss not to jump at the chance to acquire a facility like this one with a proven history of regulatory approval and commercial manufacturing. With today’s state-of-the-art monoclonal antibody production processes, this facility could easily produce 250 Kg or more of bulk monoclonal antibody per year. If you are interested in learning more about this internationally approved commercial facility, please contact me or Tom Sullivan of CBRE.

 

Blog article by: Howard Levine